PFCS
PTHS

Pale Fire Capital SE’s Pelthos Therapeutics PTHS Stock Holding History

Pale Fire Capital SE’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$365K Hold
12,919
– – 0.03% 52
2026
Q1 		$271K Buy
12,919
+4,819
+59% +$114K 0.02% 47
2025
Q4 		$251K Buy
+8,100
New +$234K 0.02% 44

Other funds holding PTHS

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return

Pale Fire Capital SE's PTHS Position: Q2 2026 in Review

Pale Fire Capital SE held its Pelthos Therapeutics (PTHS) position steady in Q2 2026 at 12,919 shares worth $365K. The position accounts for 0.03% of the portfolio, ranked #52.

Pale Fire Capital SE first reported a position in PTHS in Q4 2025 and has held it in 3 quarters since. 24 funds tracked by Wall St. Rank hold PTHS as of Q2 2026.

  • Pale Fire Capital SE held 12,919 shares of Pelthos Therapeutics worth $365K as of Q2 2026.
  • Pale Fire Capital SE left its Pelthos Therapeutics share count unchanged in Q2 2026.
  • Pelthos Therapeutics made up 0.03% of Pale Fire Capital SE's portfolio in Q2 2026, its #52 holding.
  • Pale Fire Capital SE first reported a position in Pelthos Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 24 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q2 2026.

Based on Pale Fire Capital SE's 13F filing for Q2 2026, filed 13 Aug 2026.